162 related articles for article (PubMed ID: 35534911)
1. Ectopic parathyroid hormone as a rare aetiology of hypercalcemia with rhabdomyosarcoma: a new treatment strategy with zoledronic acid and Denosumab.
Kilci F; Demirsoy U; Jones JH; Çakır Ö; Çizmecioğlu-Jones FM
J Pediatr Endocrinol Metab; 2022 Aug; 35(8):1107-1112. PubMed ID: 35534911
[TBL] [Abstract][Full Text] [Related]
2. Treatment of Hypercalcemia of Malignancy.
Chakhtoura M; El-Hajj Fuleihan G
Endocrinol Metab Clin North Am; 2021 Dec; 50(4):781-792. PubMed ID: 34774248
[TBL] [Abstract][Full Text] [Related]
3. Hypercalcemia of Malignancy Attributed to Cosecretion of PTH and PTHRP in Lung Adenocarcinoma.
Kroopnick JM; Martinez-Outschoorn U; Tuluc M; Kim CS
AACE Clin Case Rep; 2021; 7(3):200-203. PubMed ID: 34095488
[TBL] [Abstract][Full Text] [Related]
4. Successful Management of Severe Hypercalcemia with Zoledronic Acid: A Report of Two Pediatric Cases.
Kilci F; Jones JH; Çizmecioğlu-Jones FM
J Clin Res Pediatr Endocrinol; 2024 May; 16(2):224-228. PubMed ID: 36264042
[TBL] [Abstract][Full Text] [Related]
5. Control of Refractory Hypercalcemia with Denosumab in a Case of Metastatic Parathyroid Carcinoma.
Çalapkulu M; Gul OO; Cander S; Ersoy C; Erturk E; Sagiroglu MF; Saraydaroglu O
J Coll Physicians Surg Pak; 2020 Jul; 30(7):757-759. PubMed ID: 32811610
[TBL] [Abstract][Full Text] [Related]
6. Mitigating the Denosumab-Induced Rebound Phenomenon with Alternating Short- and Long-Acting Anti-resorptive Therapy in a Young Boy with Severe OI Type VI.
Seale E; Molina MO; Carsen S; Sheffield H; Koujok K; Robinson ME; Feber J; Smit K; Page M; Walker S; Khan N; Konji VN; Rauch F; Ward LM
Calcif Tissue Int; 2023 May; 112(5):613-620. PubMed ID: 36867194
[TBL] [Abstract][Full Text] [Related]
7. Elevated levels of circulating fibroblast growth factor 23 with hypercalcemia following discontinuation of denosumab.
Uchida T; Yamaguchi H; Kushima C; Yonekawa T; Nakazato M
Endocr J; 2020 Jan; 67(1):31-35. PubMed ID: 31527321
[TBL] [Abstract][Full Text] [Related]
8. The emerging role of denosumab in the long-term management of parathyroid carcinoma-related refractory hypercalcemia.
Fountas A; Andrikoula M; Giotaki Z; Limniati C; Tsakiridou E; Tigas S; Tsatsoulis A
Endocr Pract; 2015 May; 21(5):468-73. PubMed ID: 25667369
[TBL] [Abstract][Full Text] [Related]
9. Meta-analysis comparing denosumab and zoledronic acid for treatment of bone metastases in patients with advanced solid tumours.
Zheng GZ; Chang B; Lin FX; Xie D; Hu QX; Yu GY; Du SX; Li XD
Eur J Cancer Care (Engl); 2017 Nov; 26(6):. PubMed ID: 27430483
[TBL] [Abstract][Full Text] [Related]
10. Denosumab is Effective for Controlling Serum Calcium Levels in Patients with Humoral Hypercalcemia of Malignancy Syndrome: A Case Report on Parathyroid Hormone-related Protein-producing Cholangiocarcinoma.
Ashihara N; Nakajima K; Nakamura Y; Kobayashi M; Shirahata K; Maeda C; Uehara T; Gomi D; Ito N
Intern Med; 2016; 55(23):3453-3457. PubMed ID: 27904108
[TBL] [Abstract][Full Text] [Related]
11. Rare association between penile squamous cell carcinoma and parathyroid related peptide (PTH-rP) secretion.
Trejo-Rosales R; Nevarez-Barragan MJ; Rosas-Jurado MG; Perez-Diaz I; Bezaury AP
Arq Bras Endocrinol Metabol; 2014 Aug; 58(6):646-9. PubMed ID: 25211448
[TBL] [Abstract][Full Text] [Related]
12. Denosumab for patients with persistent or relapsed hypercalcemia of malignancy despite recent bisphosphonate treatment.
Hu MI; Glezerman I; Leboulleux S; Insogna K; Gucalp R; Misiorowski W; Yu B; Ying W; Jain RK
J Natl Cancer Inst; 2013 Sep; 105(18):1417-20. PubMed ID: 23990665
[TBL] [Abstract][Full Text] [Related]
13. Denosumab for treatment of hypercalcemia of malignancy.
Hu MI; Glezerman IG; Leboulleux S; Insogna K; Gucalp R; Misiorowski W; Yu B; Zorsky P; Tosi D; Bessudo A; Jaccard A; Tonini G; Ying W; Braun A; Jain RK
J Clin Endocrinol Metab; 2014 Sep; 99(9):3144-52. PubMed ID: 24915117
[TBL] [Abstract][Full Text] [Related]
14. Switching from zoledronic acid to denosumab increases the risk for developing medication-related osteonecrosis of the jaw in patients with bone metastases.
Ikesue H; Doi K; Morimoto M; Hirabatake M; Muroi N; Yamamoto S; Takenobu T; Hashida T
Cancer Chemother Pharmacol; 2021 Jun; 87(6):871-877. PubMed ID: 33791853
[TBL] [Abstract][Full Text] [Related]
15. Denosumab for the Treatment of Hypercalcemia in a Patient With Parathyroid Carcinoma: A Case Report.
Roukain A; Alwan H; Bongiovanni M; Sykiotis GP; Kopp PA
Front Endocrinol (Lausanne); 2021; 12():794988. PubMed ID: 35173680
[TBL] [Abstract][Full Text] [Related]
16. Hypercalcaemia secondary to ectopic parathyroid hormone expression in an adolescent with metastatic alveolar rhabdomyosarcoma.
Brooks R; Lord C; Davies JH; Gray JC
Pediatr Blood Cancer; 2018 Jan; 65(1):. PubMed ID: 28843052
[TBL] [Abstract][Full Text] [Related]
17. Hypercalcemia and elevated serum parathyroid hormone level in association with rhabdomyosarcoma.
Elomaa I; Lehto VP; Selander RK
Arch Pathol Lab Med; 1984 Sep; 108(9):701-3. PubMed ID: 6547822
[TBL] [Abstract][Full Text] [Related]
18. Denosumab for the treatment of bisphosphonate resistant hypercalcemia in a hemodialysis patient.
Dahmani O; Sophoclis C; Kebir M; Bouguern D; Sakho A; Demarchi P
Saudi J Kidney Dis Transpl; 2017; 28(1):154-157. PubMed ID: 28098117
[TBL] [Abstract][Full Text] [Related]
19. Denosumab vs. zoledronic acid treatment in post-menopausal breast cancer: a 2-year prospective observational study.
Buch-Larsen K; Jørgensen NR; Jensen LT; Andersson M; Schwarz P
Scand J Clin Lab Invest; 2021 Oct; 81(6):425-431. PubMed ID: 34120544
[TBL] [Abstract][Full Text] [Related]
20. Comparison of the efficacy, adverse effects, and cost of zoledronic acid and denosumab in the treatment of osteoporosis.
Sheedy KC; Camara MI; Camacho PM
Endocr Pract; 2015 Mar; 21(3):275-9. PubMed ID: 25370317
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
